Terms: = Leukemia AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM
170 results:
1. Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies.
Rees MJ; D'Agostino M; Leypoldt LB; Kumar S; Weisel KC; Gay F
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433520. PubMed ID: 38772002
[TBL] [Abstract] [Full Text] [Related]
2. Investigating the potential of single-cell DNA methylation data to detect allele-specific methylation and imprinting.
Johnson ND; Cutler DJ; Conneely KN
Am J Hum Genet; 2024 Apr; 111(4):654-667. PubMed ID: 38471507
[TBL] [Abstract] [Full Text] [Related]
3. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Gagelmann N; Dima D; Merz M; Hashmi H; Ahmed N; Tovar N; Oliver-Caldés A; Stölzel F; Rathje K; Fischer L; Born P; Schäfer L; Albici AM; Schub N; Kfir-Erenfeld S; Assayag M; Asherie N; Wulf GG; Kharboutli S; Müller F; Shune L; Davis JA; Anwer F; Vucinic V; Platzbecker U; Ayuk F; Kröger N; Khouri J; Gurnari C; McGuirk J; Stepensky P; Abdallah AO; Fernández de Larrea C
J Clin Oncol; 2024 May; 42(14):1665-1675. PubMed ID: 38358946
[TBL] [Abstract] [Full Text] [Related]
4. Engineered T cells secreting anti-bcma T cell engagers control multiple myeloma and promote immune memory in vivo.
Díez-Alonso L; Falgas A; Arroyo-Ródenas J; Romencín PA; Martínez A; Gómez-Rosel M; Blanco B; Jiménez-Reinoso A; Mayado A; Pérez-Pons A; Aguilar-Sopeña Ó; Ramírez-Fernández Á; Segura-Tudela A; Perez-Amill L; Tapia-Galisteo A; Domínguez-Alonso C; Rubio-Pérez L; Jara M; Solé F; Hangiu O; Almagro L; Albitre Á; Penela P; Sanz L; Anguita E; Valeri A; García-Ortiz A; Río P; Juan M; Martínez-López J; Roda-Navarro P; Martín-Antonio B; Orfao A; Menéndez P; Bueno C; Álvarez-Vallina L
Sci Transl Med; 2024 Feb; 16(734):eadg7962. PubMed ID: 38354229
[TBL] [Abstract] [Full Text] [Related]
5. Real-world analysis of teclistamab in 123 RRMM patients from Germany.
Riedhammer C; Bassermann F; Besemer B; Bewarder M; Brunner F; Carpinteiro A; Einsele H; Faltin J; Frenking J; Gezer D; Goldman-Mazur S; Hänel M; Hoegner M; Kortuem KM; Krönke J; Kull M; Leitner T; Mann C; Mecklenbrauck R; Merz M; Morgner A; Nogai A; Raab MS; Teipel R; Wäsch R; Rasche L
Leukemia; 2024 Feb; 38(2):365-371. PubMed ID: 38245601
[TBL] [Abstract] [Full Text] [Related]
6. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Fischer L; Grieb N; Born P; Weiss R; Seiffert S; Boldt A; Fricke S; Franz P; Heyn S; Kubasch AS; Baber R; Weidner H; Wang SY; Bach E; Hoffmann S; Ussmann J; Kirchberg J; Hell S; Schwind S; Metzeler KH; Herling M; Jentzsch M; Franke GN; Sack U; Reiche K; Köhl U; Platzbecker U; Vucinic V; Merz M
Leukemia; 2024 Feb; 38(2):372-382. PubMed ID: 38184754
[TBL] [Abstract] [Full Text] [Related]
7. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies.
Zhang Z; Markmann C; Yu M; Agarwal D; Rostami S; Wang W; Liu C; Zhao H; Ochoa T; Parvathaneni K; Xu X; Li E; Gonzalez V; Khadka R; Hoffmann J; Knox JJ; Scholler J; Marcellus B; Allman D; Fraietta JA; Samelson-Jones B; Milone MC; Monos D; Garfall AL; Naji A; Bhoj VG
Cell Rep Med; 2023 Dec; 4(12):101336. PubMed ID: 38118406
[TBL] [Abstract] [Full Text] [Related]
8. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract] [Full Text] [Related]
9. [Novel CD19-KIRS2/Dap12-BB CAR-T Treatment for 3 Patients with Relapsed and Refractory B-Cell Tumors].
Ji SW; Hua T; Wang JJ; Shao LY; Chen ZH; Liu JY; Cheng H; Chen W; Sun C; Wang X; Xu KL; Cao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1860-1865. PubMed ID: 38071073
[TBL] [Abstract] [Full Text] [Related]
10. [Clinical analysis of long-term survival and influencing factors of chimeric antigen receptor T-cell therapy in relapsed/refractory acute B-cell lymphoblastic leukemia].
Wang Y; Gao QY; Wang H; Zhang D; Gao Y; Miao YD; Zhai XH; Hu XX; Rui XL; Zhang WH
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):800-804. PubMed ID: 38049330
[No Abstract] [Full Text] [Related]
11. [Development of Novel Gene-Modified T-Cell Therapies(CAR-T, TCR-T)].
Kitano S
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1032-1037. PubMed ID: 38035829
[TBL] [Abstract] [Full Text] [Related]
12. Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
Garcia-Pouton N; Ortiz-Maldonado V; Peyrony O; Chumbita M; Aiello TF; Monzo-Gallo P; Lopera C; Puerta-Alcalde P; Magnano L; Martinez-Cibrian N; Pitart C; Juan M; Delgado J; Fernandez De Larrea C; Soriano Á; Urbano-Ispizua Á; Garcia-Vidal C
Eur J Haematol; 2024 Mar; 112(3):371-378. PubMed ID: 37879842
[TBL] [Abstract] [Full Text] [Related]
13. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.
Hashmi H; Hansen DK; Peres LC; Puglianini OC; Freeman C; De Avila G; Sidana S; Shune L; Sborov DW; Davis J; Wagner C; Kocoglu MH; Atrash S; Voorhees P; Simmons G; Ferreri C; Kalariya N; Anderson LD; Afrough A; Dima D; Khouri J; McGuirk J; Locke F; Baz R; Patel KK; Alsina M
Haematologica; 2024 May; 109(5):1514-1524. PubMed ID: 37855036
[TBL] [Abstract] [Full Text] [Related]
14. Bispecific CS1-bcma CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
Li C; Xu J; Luo W; Liao D; Xie W; Wei Q; Zhang Y; Wang X; Wu Z; Kang Y; Zheng J; Xiong W; Deng J; Hu Y; Mei H
Leukemia; 2024 Jan; 38(1):149-159. PubMed ID: 37848634
[TBL] [Abstract] [Full Text] [Related]
15. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies.
Kampouri E; Little JS; Rejeski K; Manuel O; Hammond SP; Hill JA
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14157. PubMed ID: 37787373
[TBL] [Abstract] [Full Text] [Related]
16. bcma-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
Fang J; Zhou F
Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
[TBL] [Abstract] [Full Text] [Related]
17. CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.
Golubovskaya V; Sienkiewicz J; Sun J; Zhang S; Huang Y; Zhou H; Harto H; Xu S; Berahovich R; Wu L
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686170
[TBL] [Abstract] [Full Text] [Related]
18. Mechanisms of antigen escape from bcma- or GPRC5D-targeted immunotherapies in multiple myeloma.
Lee H; Ahn S; Maity R; Leblay N; Ziccheddu B; Truger M; Chojnacka M; Cirrincione A; Durante M; Tilmont R; Barakat E; Poorebrahim M; Sinha S; McIntyre J; M Y Chan A; Wilson H; Kyman S; Krishnan A; Landgren O; Walter W; Meggendorfer M; Haferlach C; Haferlach T; Einsele H; Kortüm MK; Knop S; Alberge JB; Rosenwald A; Keats JJ; Rasche L; Maura F; Neri P; Bahlis NJ
Nat Med; 2023 Sep; 29(9):2295-2306. PubMed ID: 37653344
[TBL] [Abstract] [Full Text] [Related]
19. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior bcma-targeted therapy.
Ferreri CJ; Hildebrandt MAT; Hashmi H; Shune LO; McGuirk JP; Sborov DW; Wagner CB; Kocoglu MH; Rapoport A; Atrash S; Voorhees PM; Khouri J; Dima D; Afrough A; Kaur G; Anderson LD; Simmons G; Davis JA; Kalariya N; Peres LC; Lin Y; Janakiram M; Nadeem O; Alsina M; Locke FL; Sidana S; Hansen DK; Patel KK; Castaneda Puglianini OA
Blood Cancer J; 2023 Aug; 13(1):117. PubMed ID: 37558706
[TBL] [Abstract] [Full Text] [Related]
20. Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia.
Feng Y; Chen T; Zhang Y; Yao H; Wang P; Wang L; Cassady K; Zou Z; Liu Y; Zhao L; Gao L; Zhang X; Kong P
Front Immunol; 2023; 14():1182251. PubMed ID: 37435080
[TBL] [Abstract] [Full Text] [Related]
[Next]
